Navigation Links
Drug for Treatment of Heart Failure Does Not Improve Survival,,Compared to More Widely-used Medication

CHICAGO, May 1, 2007—The drug levosimendan did not improve survival for patients with decompensated heart failure when compared with a more widely-used treatment for this condition, dobutamine, according to a study in the May 2 issue of JAMA.

Acute decompensated heart failure (ADHF; severe heart failure characterized by inability of the heart to maintain adequate blood circulation) remains a common cause of hospitalization worldwide, but appropriate treatment is not always clear. Dobutamine improves symptoms but has been associated with an increased risk of death and other cardiovascular events, according to background information in the article. In a previous study, secondary analyses indicated that the drug levosimendan was associated with lower risk of death compared to dobutamine.

Alexandre Mebazaa, M.D., Ph.D., of the Université Paris Diderot and Hospital Lariboisiére AP-HP, Paris, and colleagues with the SURVIVE trial (Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support) conducted a study in which the primary purpose of the trial was to assess long-term survival outcomes for 1,327 ADHF patients who received levosimendan or dobutamine. The trial was conducted at 75 centers in 9 countries and patients were randomized between March 2003 and December 2004. Patients received either intravenous levosimendan (n = 664) or intravenous dobutamine (n = 663).

The researchers found that during the 180 days after drug infusion, there were 173 deaths (26 percent) in the levosimendan group and 185 deaths in the dobutamine group (28 percent). There were no statistical differences between treatment groups for most secondary end points (all-cause death at 31 days, number of days alive and out of the hospital, patient global assessment, patient assessment of dyspnea (difficulty breathing) at 24 hours, and cardiovascular death at 180 days). C
'"/>




Page: 1 2

Related medicine technology :

1. Point of Care Strep Tests Speed Treatment, Lower Costs
2. Rapid HIV Testing Increases Possibility of Treatment
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
10. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
11. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
Post Your Comments:
(Date:12/4/2009)... Dynatronics Corporation (Nasdaq: DYNT ) announced it ... equipment and rehab supplies to Benchmark Physical Therapy with ... "We are pleased to be named the sole-source supplier ... vice president of sales and marketing at Dynatronics. "Benchmark ...
(Date:12/4/2009)... Chemistry World recently highlighted a new ... of America ( PhRMA ) that identifies 97 new ... ,, The report found that the 97 products ... are either in human clinical trials or awaiting approval by ...
(Date:12/4/2009)... PharmAthene, Inc. (NYSE Amex: PIP ), a ... chemical threats, announced today that the Company is ... of Valortim® in an inhalation anthrax model in ... data are being presented during an oral session ...
Breaking Medicine Technology:U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6Pumgo Fitness Scooter Will Highlight Venice Beach This Summer 49639 1Pumgo Fitness Scooter Will Highlight Venice Beach This Summer 49639 2Crown Consumer Brands Re Launches DentaBurst 28TM 29 Freshening Teeth Cleaners 49636 1Crown Consumer Brands Re Launches DentaBurst 28TM 29 Freshening Teeth Cleaners 49636 2MUSCLEPHARM Products Hit Vitamin Shoppe Shelves With a Bang 21 49633 1MUSCLEPHARM Products Hit Vitamin Shoppe Shelves With a Bang 21 49633 2
... studies are few, NEW YORK, Aug. 13 ... a limited amount of clinical research exists,to prove ... study is published in the July/August 2007 issue ... of the,American Society for Aesthetic Plastic Surgery (ASAPS). ...
... Aug. 14 Immtech Pharmaceuticals,Inc. (Amex: IMM ... in Nucleic,Acids Research by a group of researchers ... furamidine to inhibit a key enzyme involved in ... the active metabolite (DB75),of Immtech,s proprietary, orally bioavailable ...
Other Medicine Technology:OTC Anti-Aging Products: Hype or Hope? 2Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms 2Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms 3
(Date:12/6/2009)... new study by researchers from the Medical College of ... utilization for pain and other sickle cell disease complications ... of both providers and patients were also identified. ... assistant professor of pediatrics at the Medical College and ... will be presented at the American Society of Hematology ...
(Date:12/6/2009)... new study provides welcome news for patients with a ... , The condition is estimated to impact 62,000 Canadians ... abnormal clot forms in a vein and restricts the ... cases, the clot may detach from its point of ... causing a potentially fatal condition known as a pulmonary ...
(Date:12/5/2009)... in a phase 1/2 clinical trial that it ... patients newly diagnosed with multiple myeloma, a cancer of ... Dana-Farber Cancer Institute. , Partial responses or better were ... the drug combination in the multi-center study, with 74 ... the phase 2 population, reports Paul G. Richardson, MD, ...
(Date:12/5/2009)... Babies, This Type of Blood Cancer Is Most Challenging-- ... Pediatric oncologists have identified specific genes, dubbed partner ... often-fatal form of leukemia in infants. By more accurately ... which infants may benefit from particular treatments. ,, ...
(Date:12/5/2009)... Center helps companies develop and test their cleaning processes. The technology ... of industries and solve problems for customers relating to cleaning parts, ... ... 2009 -- Midbrook, Inc , a Jackson, MI-based company, is ...
Breaking Medicine News(10 mins):Health News:New study finds barriers to pain treatment in children with sickle cell disease 2Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:Multiple myeloma patients experience high response rate with new 3-drug combination 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 3Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 4Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3
... According to a recent study conducted by researchers at ... lead to a rise of certain// chemicals in the ... brain and nerve cell damage. This increase of chemicals ... and symptoms of lasting neurological damage. ,This ...
... published in PLoS Medicine online says that the life expectancy ... an Asian-American woman may live// two decades longer than an ... evidence is really quite clear that most of the gap ... young and middle-aged adult men and women and most of ...
... Sreemathy today visited the community health centre at Vizhinjam and ... of viral fever//. ,"In Tamil Nadu, the number ... managed to prevent the fever spreading further along the coast," ... day in August, but on Saturday the number was just ...
... the safest pain medication? Many people with osteoarthritis ... the painkillers called COX-2 inhibitors// to increased heart ... from a COX-2 drug to other medications, including ... and naproxen. But although NSAIDs are effective at ...
... the positive influence of having a baby and its benefits ... this research seem to suggest that women who are childless ... lives and may even face early death. ,According ... age are 20% more likely to die than their contemporaries, ...
... saw the conclusion of the first of a wave of ... as Wyeth defended// its hormone replacement therapy Prempro against claims ... ,Zoe Littlepage, an attorney for plaintiff Linda Reeves, told the ... was negligent in not testing the drug and not knowing ...
Other Medicine News:Health News:Punch-Drunk Effect- Every blow matters 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: